Switch theme
Sign up to access all valuation multiples
Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
1988
15.1K+
LTM Revenue $14.2B
LTM EBITDA $5.4B
$56.1B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Regeneron Pharmaceuticals has a last 12-month revenue of $14.2B and a last 12-month EBITDA of $5.4B.
In the most recent fiscal year, Regeneron Pharmaceuticals achieved revenue of $14.2B and an EBITDA of $5.3B.
Regeneron Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Regeneron Pharmaceuticals valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $13.1B | $14.2B | XXX | XXX | XXX |
| Gross Profit | $10.6B | $11.3B | XXX | XXX | XXX |
| Gross Margin | 81% | 80% | XXX | XXX | XXX |
| EBITDA | $4.7B | $5.3B | XXX | XXX | XXX |
| EBITDA Margin | 36% | 37% | XXX | XXX | XXX |
| Net Profit | $4.3B | $4.0B | XXX | XXX | XXX |
| Net Margin | 33% | 28% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Regeneron Pharmaceuticals's stock price is $571.
Regeneron Pharmaceuticals has current market cap of $62.4B, and EV of $56.1B.
See Regeneron Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $56.1B | $62.4B | XXX | XXX | XXX | XXX | $44.27 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Regeneron Pharmaceuticals has market cap of $62.4B and EV of $56.1B.
Regeneron Pharmaceuticals's trades at 3.9x LTM EV/Revenue multiple, and 10.4x LTM EBITDA.
Analysts estimate Regeneron Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Regeneron Pharmaceuticals and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $56.1B | XXX | XXX | XXX |
| EV/Revenue | 4.0x | XXX | XXX | XXX |
| EV/EBITDA | 10.6x | XXX | XXX | XXX |
| P/E | 14.1x | XXX | XXX | XXX |
| P/E/Growth | 1.7x | XXX | XXX | XXX |
| EV/FCF | 15.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpRegeneron Pharmaceuticals's NTM/LTM revenue growth is 3%
Regeneron Pharmaceuticals's revenue per employee for the last fiscal year averaged $0.9M, while opex per employee averaged $0.5M for the same period.
Over next 12 months, Regeneron Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Regeneron Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Regeneron Pharmaceuticals and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 8% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 37% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 13% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 40% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.9M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.5M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 36% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 57% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Regeneron Pharmaceuticals acquired XXX companies to date.
Last acquisition by Regeneron Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Regeneron Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Regeneron Pharmaceuticals founded? | Regeneron Pharmaceuticals was founded in 1988. |
| Where is Regeneron Pharmaceuticals headquartered? | Regeneron Pharmaceuticals is headquartered in United States of America. |
| How many employees does Regeneron Pharmaceuticals have? | As of today, Regeneron Pharmaceuticals has 15.1K+ employees. |
| Who is the CEO of Regeneron Pharmaceuticals? | Regeneron Pharmaceuticals's CEO is Dr. Leonard S. Schleifer,M.D.,PhD. |
| Is Regeneron Pharmaceuticals publicy listed? | Yes, Regeneron Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of Regeneron Pharmaceuticals? | Regeneron Pharmaceuticals trades under REGN ticker. |
| When did Regeneron Pharmaceuticals go public? | Regeneron Pharmaceuticals went public in 1991. |
| Who are competitors of Regeneron Pharmaceuticals? | Similar companies to Regeneron Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Regeneron Pharmaceuticals? | Regeneron Pharmaceuticals's current market cap is $62.4B |
| What is the current revenue of Regeneron Pharmaceuticals? | Regeneron Pharmaceuticals's last 12-month revenue is $14.2B. |
| What is the current EBITDA of Regeneron Pharmaceuticals? | Regeneron Pharmaceuticals's last 12-month EBITDA is $5.4B. |
| What is the current EV/Revenue multiple of Regeneron Pharmaceuticals? | Current revenue multiple of Regeneron Pharmaceuticals is 3.9x. |
| What is the current EV/EBITDA multiple of Regeneron Pharmaceuticals? | Current EBITDA multiple of Regeneron Pharmaceuticals is 10.4x. |
| What is the current revenue growth of Regeneron Pharmaceuticals? | Regeneron Pharmaceuticals revenue growth between 2023 and 2024 was 8%. |
| Is Regeneron Pharmaceuticals profitable? | Yes, Regeneron Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
